Verisante Technology said this week that it has signed an exclusive agreement with Frontière Médicale EUROPE for distribution of its Verisante Aura skin cancer detection device in the UK and Ireland.

With the agreement, Verisante now has distribution agreements for the Aura in Canada, Germany, Austria, Liechtenstein, Switzerland, the UK, and Ireland. The company began sales of the device at the beginning of the year, and recognized $235,000 in revenue from it for the quarter ended March 21, 2013.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.